Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$2.91M$2.91Mno prior Q1 2021 on file Net Income-$1.35M-$1.35Mno prior Q1 2021 on file EPS, diluted—
Operating Income-$1,376,000— The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,424,000— Free Cash Flowderived-$1,450,000— Margins · derivedGross margin49.5%
Operating margin-47.3%
Net margin-46.3%
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end